Azienda Ospedaliero - Universitaria San Luigi Gonzaga
Welcome,         Profile    Billing    Logout  
 59 Trials 
91 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wislez, Marie
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/24
12/26
COMET, NCT06908993: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Not yet recruiting
3
133
Europe
Tepotinib, Pemetrexed (Alimta), Vinorelbine, Gemcitabine alone, Docetaxel, Paclitaxel, Pembrolizumab, Nivolumab, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
03/28
07/28
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting
2
80
Europe, RoW
Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736
Centre Leon Berard, Groupe Français de Pneumo-Cancérologie
Large Cell Neuroendocrine Carcinoma of the Lung
09/28
09/29
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
SPORADIC, NCT06656598: Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
Lung KG12Ci, NCT05273047: RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Active, not recruiting
N/A
458
Europe
Intergroupe Francophone de Cancerologie Thoracique, Amgen
Nsclc, KRAS P.G12C
08/23
12/24
RESAMEX, NCT06247826: Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Recruiting
N/A
30
Europe
Blood sampling
Groupe Francais De Pneumo-Cancerologie
Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
09/25
09/25
PNN-CP, NCT06244355: Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer

Recruiting
N/A
100
Europe
Extra blood tubes
Assistance Publique - Hôpitaux de Paris
Lung Cancer
06/26
12/26
CASCADE, NCT05195385: Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

Recruiting
N/A
2635
Europe
Low-dose computed tomography of the chest
Assistance Publique - Hôpitaux de Paris, Ministère de la Santé et des Solidarités, National Cancer Institute, France
Lung Cancer Screening
10/27
10/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
PACT-01, NCT04823377: Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

Recruiting
N/A
364
Europe
Usual care, Optimization of the medical decision
Institut Curie
Carcinoma, Non-Small-Cell Lung, Advanced Cancer
09/26
09/27
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31
Isambert, Nicolas
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
CIRSARC, NCT03805022 / 2018-000186-36: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
CHIC-STS01, NCT04307277 / 2019-003014-13: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Recruiting
3
600
Europe
Standard of care + chemotherapy, Standard of care
Institut Claudius Regaud, Direction Générale de l’Offre de Soins (DGOS)
Soft Tissue Sarcoma
10/32
10/32
MOIO, NCT05078047 / 2021-000615-23: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Recruiting
3
646
Europe
Reduced dose intensity of IO
UNICANCER, PHRC-K 2020, Fondation BMS
Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma, Colorectal Carcinoma With Microsatellite Instability, Esophageal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Cancer, Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma, Basal Cell Carcinoma, Squamous Skin Carcinoma
03/25
03/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CAIRE, NCT04705818 / 2019-003303-35: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Completed
2
77
Europe
Lenvatinib, Placebo, Best supportive care
Centre Leon Berard
Gastro Intestinal Stromal Tumour
01/24
04/24
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Completed
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
09/24
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Terminated
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
AGADIR, NCT03915678 / 2019-000850-78: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
TRUST, NCT04874311 / 2020-005703-39: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
2
80
Europe
Bintrafusp alfa, Doxorubicin
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
09/24
03/25
TARSARC, NCT04807816 / 2018-003835-31: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Recruiting
2
110
Europe
Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec®
Centre Leon Berard
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
10/27
10/27
INDIGO, NCT06713798: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
115
Europe
Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV
Gustave Roussy, Cancer Campus, Grand Paris, Roche Global Development
Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer
01/28
01/30
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
RIBOLARIS, NCT05296746 / 2021-002322-24: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Recruiting
2
1100
Europe
Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant)
SOLTI Breast Cancer Research Group, Novartis, UNICANCER
Breast Cancer Stage II
10/29
12/31
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
DF6215-001, NCT06108479: Study of DF6215 in Patients with Advanced Solid Tumors

Recruiting
1
255
Europe, US, RoW
DF6215, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Solid Tumor Cancer
03/26
12/27
OncoSNIPE, NCT04548960: - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

Recruiting
N/A
600
Europe
cancer patients
Oncodesign SA
CANCER
12/21
03/23
EXOSARC, NCT03800121: Study of Exosomes in Monitoring Patients With Sarcoma

Recruiting
N/A
34
Europe
Blood samples, Localized sarcoma, Metastatic sarcoma
Centre Georges Francois Leclerc
Sarcoma
11/24
11/25
RNASARC, NCT03375437: - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.

Active, not recruiting
N/A
376
Europe
Blood and tumor samples
Centre Leon Berard, Hoffmann-La Roche
Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer
12/24
12/25
NEOSarcomics, NCT02789384: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

Recruiting
N/A
205
Europe
Procedure/Surgery
Institut Bergonié, National Cancer Institute, France, Ministry of Health, France
Soft-tissue Sarcomas
01/25
08/27
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
REGOSTA, NCT04055220 / 2018-004045-16: Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Recruiting
N/A
168
Europe
Treatment by Regorafenib, Stivarga, Treatment by Placebo, Standard of care
Centre Leon Berard
Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma
10/26
10/26
MIRAS, NCT03967834: Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Recruiting
N/A
400
Europe
Patient with Soft Tissue Sarcoma
Institut Claudius Regaud
Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms, Desmoplastic Small Round Cell Tumor, Malignant Solitary Fibrous Tumors, Alveolar Soft Part Sarcoma, Epithelioid Hemangioendothelioma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
04/31
04/31
Novello, Silvia
EPIC, NCT03402048: The Trial The Elderly Patient Individualized Chemotherapy Trial

Recruiting
3
567
Europe
Carboplatin, Gemcitabine, Gemzar, Pemetrexed, Alimta, Docetaxel, Taxotere, Vinorelbine, Navelbine
University of Turin, Italy
Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms
12/20
05/21
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
07/27
06/29
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/28
12/31
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting
2
206
Europe
Atezolizumab, Bevacizumab
Fondazione Ricerca Traslazionale
Non-small-cell Lung Cancer Patients
05/22
04/23
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Active, not recruiting
2
43
Europe
Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080
MedSIR, Merck Sharp & Dohme LLC
Metastatic Thymic Carcinoma, Thymoma Type B3
07/24
01/26
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
UNITO-001, NCT04940637: - Study in HRR/PDL1 Positive MPM/NSCLC

Recruiting
2
70
Europe
niraparib and dostarlimab, no other intervention
University of Turin, Italy
Lung Cancer, Mesothelioma
06/24
06/25
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
NCT06669117: FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.

Recruiting
1
94
Europe
IL12-L19L19, Dodekin
Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
12/25
12/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Lee, Dae Ho
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT06669117: FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Active, not recruiting
1/2
97
Europe, US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting
N/A
640
RoW
Atrial sensing On mode
Samsung Medical Center, Biotronik SE & Co. KG
Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia
12/21
05/23
NCT06070896: Advanced Modeling of the Evolution of the Epidemiological Outbreak of SARS-CoV-2 Pandemic

Completed
N/A
715206
Europe
Hospital Galdakao-Usansolo, Basque Government Department of Public Health, University of the Basque Country (UPV/EHU), BCAM (Basque Center for Applied Mathematics), Osakidetza
COVID-19
09/22
12/23
NCT03274869: Scrub Typhus Infection Induced Cardiovascular Disease

Active, not recruiting
N/A
100
RoW
No intervention
Eulji University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Chungbuk National University Hospital
Scrub Typhus, Cardiovascular Complication
09/26
08/27
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care

Recruiting
N/A
94
RoW
Experimental group
Kyunghee University Medical Center
Sarcopenia
12/24
12/24
Picchi, Hugo
ALBAN, NCT03799835 / 2017-004512-19: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting
3
517
Europe
BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq®
UNICANCER, Hoffmann-La Roche
Bladder Cancer
06/25
10/28
BLAD-RAD01, NCT04428554: Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

Recruiting
2
130
Europe
Experimental arm
Institut Claudius Regaud
Urothelial Bladder Cancer
07/28
07/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wislez, Marie
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/24
12/26
COMET, NCT06908993: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Not yet recruiting
3
133
Europe
Tepotinib, Pemetrexed (Alimta), Vinorelbine, Gemcitabine alone, Docetaxel, Paclitaxel, Pembrolizumab, Nivolumab, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
03/28
07/28
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
560
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
FIRST-NEC, NCT06393816: (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting
2
80
Europe, RoW
Durvalumab with etoposide and Carboplatin/Cisplatin, MEDI4736
Centre Leon Berard, Groupe Français de Pneumo-Cancérologie
Large Cell Neuroendocrine Carcinoma of the Lung
09/28
09/29
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
SPORADIC, NCT06656598: Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
Lung KG12Ci, NCT05273047: RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

Active, not recruiting
N/A
458
Europe
Intergroupe Francophone de Cancerologie Thoracique, Amgen
Nsclc, KRAS P.G12C
08/23
12/24
RESAMEX, NCT06247826: Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Recruiting
N/A
30
Europe
Blood sampling
Groupe Francais De Pneumo-Cancerologie
Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
09/25
09/25
PNN-CP, NCT06244355: Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer

Recruiting
N/A
100
Europe
Extra blood tubes
Assistance Publique - Hôpitaux de Paris
Lung Cancer
06/26
12/26
CASCADE, NCT05195385: Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study

Recruiting
N/A
2635
Europe
Low-dose computed tomography of the chest
Assistance Publique - Hôpitaux de Paris, Ministère de la Santé et des Solidarités, National Cancer Institute, France
Lung Cancer Screening
10/27
10/27
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
PACT-01, NCT04823377: Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

Recruiting
N/A
364
Europe
Usual care, Optimization of the medical decision
Institut Curie
Carcinoma, Non-Small-Cell Lung, Advanced Cancer
09/26
09/27
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31
Isambert, Nicolas
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
CIRSARC, NCT03805022 / 2018-000186-36: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
RAR-Immune, NCT04741438: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Recruiting
3
96
Europe
Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
Centre Leon Berard
Sarcoma
02/25
08/25
CHIC-STS01, NCT04307277 / 2019-003014-13: Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma

Recruiting
3
600
Europe
Standard of care + chemotherapy, Standard of care
Institut Claudius Regaud, Direction Générale de l’Offre de Soins (DGOS)
Soft Tissue Sarcoma
10/32
10/32
MOIO, NCT05078047 / 2021-000615-23: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Recruiting
3
646
Europe
Reduced dose intensity of IO
UNICANCER, PHRC-K 2020, Fondation BMS
Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Hepatocellular Carcinoma, Melanoma, Urothelial Carcinoma, Colorectal Carcinoma With Microsatellite Instability, Esophageal Squamous Cell Carcinoma, Endometrial Carcinoma, Cervical Cancer, Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma, Basal Cell Carcinoma, Squamous Skin Carcinoma
03/25
03/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CAIRE, NCT04705818 / 2019-003303-35: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

Completed
2
77
Europe
Lenvatinib, Placebo, Best supportive care
Centre Leon Berard
Gastro Intestinal Stromal Tumour
01/24
04/24
EREMISS, NCT03793361: Phase II Study of Regorafenib as Maintenance Therapy

Completed
2
127
Europe
Regorafenib, stivarga, Placebo
Centre Oscar Lambret
Metastatic Soft Tissue Sarcoma
03/24
09/24
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Terminated
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
AGADIR, NCT03915678 / 2019-000850-78: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
TRUST, NCT04874311 / 2020-005703-39: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Recruiting
2
80
Europe
Bintrafusp alfa, Doxorubicin
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
09/24
03/25
TARSARC, NCT04807816 / 2018-003835-31: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined with Atezolizumab Versus Imatinib Resumption Alone in Patients with Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

Recruiting
2
110
Europe
Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec®
Centre Leon Berard
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
10/27
10/27
INDIGO, NCT06713798: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
115
Europe
Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV
Gustave Roussy, Cancer Campus, Grand Paris, Roche Global Development
Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer
01/28
01/30
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
RIBOLARIS, NCT05296746 / 2021-002322-24: Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Recruiting
2
1100
Europe
Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant)
SOLTI Breast Cancer Research Group, Novartis, UNICANCER
Breast Cancer Stage II
10/29
12/31
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().

Completed
1/2
29
Europe, US
ANV419, Pembrolizumab, Ipilimumab
Anaveon AG, Anaveon AG
Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
08/24
08/24
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
275
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
DF6215-001, NCT06108479: Study of DF6215 in Patients with Advanced Solid Tumors

Recruiting
1
255
Europe, US, RoW
DF6215, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Solid Tumor Cancer
03/26
12/27
OncoSNIPE, NCT04548960: - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients

Recruiting
N/A
600
Europe
cancer patients
Oncodesign SA
CANCER
12/21
03/23
EXOSARC, NCT03800121: Study of Exosomes in Monitoring Patients With Sarcoma

Recruiting
N/A
34
Europe
Blood samples, Localized sarcoma, Metastatic sarcoma
Centre Georges Francois Leclerc
Sarcoma
11/24
11/25
RNASARC, NCT03375437: - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.

Active, not recruiting
N/A
376
Europe
Blood and tumor samples
Centre Leon Berard, Hoffmann-La Roche
Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer
12/24
12/25
NEOSarcomics, NCT02789384: CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.

Recruiting
N/A
205
Europe
Procedure/Surgery
Institut Bergonié, National Cancer Institute, France, Ministry of Health, France
Soft-tissue Sarcomas
01/25
08/27
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
REGOSTA, NCT04055220 / 2018-004045-16: Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Recruiting
N/A
168
Europe
Treatment by Regorafenib, Stivarga, Treatment by Placebo, Standard of care
Centre Leon Berard
Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Angiosarcoma
10/26
10/26
MIRAS, NCT03967834: Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Recruiting
N/A
400
Europe
Patient with Soft Tissue Sarcoma
Institut Claudius Regaud
Soft Tissue Sarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma, Perivascular Epithelioid Cell Neoplasms, Desmoplastic Small Round Cell Tumor, Malignant Solitary Fibrous Tumors, Alveolar Soft Part Sarcoma, Epithelioid Hemangioendothelioma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
04/31
04/31
Novello, Silvia
EPIC, NCT03402048: The Trial The Elderly Patient Individualized Chemotherapy Trial

Recruiting
3
567
Europe
Carboplatin, Gemcitabine, Gemzar, Pemetrexed, Alimta, Docetaxel, Taxotere, Vinorelbine, Navelbine
University of Turin, Italy
Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms
12/20
05/21
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
07/27
06/29
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/28
12/31
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/27
08/32
BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting
2
206
Europe
Atezolizumab, Bevacizumab
Fondazione Ricerca Traslazionale
Non-small-cell Lung Cancer Patients
05/22
04/23
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Active, not recruiting
2
43
Europe
Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080
MedSIR, Merck Sharp & Dohme LLC
Metastatic Thymic Carcinoma, Thymoma Type B3
07/24
01/26
CHANCE, NCT03976518: Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies ( Trial)

Completed
2
43
Europe
Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology, Istituto Toscano Tumori, YGHEA, CRO Division of Ecol Studio spa, Iqvia Pty Ltd, AOU S. Orsola Malpighi - Clinical Trial Office, Silvano Chiapparoli Logistica SpA, Roche SpA
Non-Small Cell Lung Cancer
02/24
02/24
UNITO-001, NCT04940637: - Study in HRR/PDL1 Positive MPM/NSCLC

Recruiting
2
70
Europe
niraparib and dostarlimab, no other intervention
University of Turin, Italy
Lung Cancer, Mesothelioma
06/24
06/25
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
NCT06669117: FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.

Recruiting
1
94
Europe
IL12-L19L19, Dodekin
Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
12/25
12/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Lee, Dae Ho
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT06669117: FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Recruiting
1/2
140
Europe, US, RoW
VERT-002
Pierre Fabre Medicament
Solid Tumor, MET Alteration
10/30
10/32
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Active, not recruiting
1/2
97
Europe, US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting
N/A
640
RoW
Atrial sensing On mode
Samsung Medical Center, Biotronik SE & Co. KG
Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia
12/21
05/23
NCT06070896: Advanced Modeling of the Evolution of the Epidemiological Outbreak of SARS-CoV-2 Pandemic

Completed
N/A
715206
Europe
Hospital Galdakao-Usansolo, Basque Government Department of Public Health, University of the Basque Country (UPV/EHU), BCAM (Basque Center for Applied Mathematics), Osakidetza
COVID-19
09/22
12/23
NCT03274869: Scrub Typhus Infection Induced Cardiovascular Disease

Active, not recruiting
N/A
100
RoW
No intervention
Eulji University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Chungbuk National University Hospital
Scrub Typhus, Cardiovascular Complication
09/26
08/27
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care

Recruiting
N/A
94
RoW
Experimental group
Kyunghee University Medical Center
Sarcopenia
12/24
12/24
Picchi, Hugo
ALBAN, NCT03799835 / 2017-004512-19: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Active, not recruiting
3
517
Europe
BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq®
UNICANCER, Hoffmann-La Roche
Bladder Cancer
06/25
10/28
BLAD-RAD01, NCT04428554: Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

Recruiting
2
130
Europe
Experimental arm
Institut Claudius Regaud
Urothelial Bladder Cancer
07/28
07/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27

Download Options